Literature DB >> 22092160

Evaluation of the hemostatic potential including thrombin generation of three different therapeutic pathogen-reduced plasmas.

M Hacquard1, T Lecompte, B Belcour, C Geschier, C Jacquot, E Jacquot, T Schneider.   

Abstract

BACKGROUND AND OBJECTIVES: Several pathogen inactivation methods currently applied to therapeutic plasma may result in products with different hemostatic properties. This study aims at evaluating and comparing the hemostatic potential of different therapeutic plasma preparations currently available in France.
MATERIALS AND METHODS: We studied three types of pathogen-reduced plasma for transfusion (MB/light, Amotosalen/UVA, industrial S/D plasma). Quarantine, non-pathogen-reduced plasma, was used as a control. This study compared more specifically the content in FVIII, fibrinogen (clottable and antigen assays) and ADAMTS-13 and evaluated the intrinsic hemostatic properties using a thrombin generation test [Calibrated Automated Thrombogram (CAT)] at high and low concentrations of tissue factor to assess the maximum quantity of thrombin generated or the contribution of FVIII and FIX in the amplification phase of thrombin generation, respectively.
RESULTS: The median FVIII concentration was >70 IU/dl for each preparation. Endogenous thrombin potential values were significantly different among the methods of plasma preparation (P<0·001) but were all in the range of the values measured in donors' plasma. Control by the thrombomodulin-activated protein C system was preserved in all preparations (>50% inhibition of endogenous thrombin potential). Fibrinogen concentrations were all within normal range but fibrinogen levels were lower in the plasmas treated with photochemical methods. ADAMTS-13 levels were preserved.
CONCLUSION: The hemostatic potential appears well preserved in all therapeutic plasmas tested but there are some differences between preparations, the clinical relevance of which remains to be elucidated.
© 2011 The Author(s). Vox Sanguinis © 2011 International Society of Blood Transfusion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22092160     DOI: 10.1111/j.1423-0410.2011.01562.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  6 in total

Review 1.  Is solvent/detergent plasma better than standard fresh-frozen plasma? A systematic review and an expert consensus document.

Authors:  Marco Marietta; Massimo Franchini; M Lucia Bindi; Francesco Picardi; Matteo Ruggeri; Giustina De Silvestro
Journal:  Blood Transfus       Date:  2016-02-17       Impact factor: 3.443

2.  The effect of pathogen inactivation on cryoprecipitate: a functional and quantitative evaluation.

Authors:  Reed W Kamyszek; Matthew W Foster; Brooke A Evans; Keaton Stoner; Jessica Poisson; Amudan J Srinivasan; J Will Thompson; M Arthur Moseley; Micah J Mooberry; Ian J Welsby
Journal:  Blood Transfus       Date:  2020-08-06       Impact factor: 3.443

3.  What Laboratory Tests and Physiologic Triggers Should Guide the Decision to Administer a Platelet or Plasma Transfusion in Critically Ill Children and What Product Attributes Are Optimal to Guide Specific Product Selection? From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding.

Authors:  Meghan Delaney; Oliver Karam; Lani Lieberman; Katherine Steffen; Jennifer A Muszynski; Ruchika Goel; Scot T Bateman; Robert I Parker; Marianne E Nellis; Kenneth E Remy
Journal:  Pediatr Crit Care Med       Date:  2022-01-01       Impact factor: 3.971

4.  Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass.

Authors:  Charles L Percy; Rudolf Hartmann; Rhidian M Jones; Subramaniam Balachandran; Dheeraj Mehta; Michael Dockal; Friedrich Scheiflinger; Valerie B O'Donnell; Judith E Hall; Peter W Collins
Journal:  Blood Coagul Fibrinolysis       Date:  2015-06       Impact factor: 1.276

Review 5.  Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data.

Authors:  José Luis Arroyo; Eva Martínez; Cristina Amunárriz; Carmen Muñoz; Iñigo Romón; Ignacio Álvarez; José María García
Journal:  Transfus Apher Sci       Date:  2020-04-12       Impact factor: 1.764

6.  Solvent/detergent plasma: pharmaceutical characteristics and clinical experience.

Authors:  Giancarlo Maria Liumbruno; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.